PDGFRα, is a tyrosine kinase receptor that, when activated by PDGF ligands, promotes fibroblast activation, tissue remodeling, and cell growth. Tovetumab's inhibition of PDGFRα aims to reduce pathological fibrosis, slow disease progression, and potentially inhibit tumor stroma formation in veterinary malignancies. Its species-specific design ensures optimal safety and efficacy in companion animals.